Last reviewed · How we verify
TP-03 Vehicle
TP-03 Vehicle is a Small molecule drug developed by Tarsus Pharmaceuticals, Inc.. It is currently in Phase 3 development for Ocular surface disease (specific indication under investigation in Phase 3).
TP-03 Vehicle is a topical ophthalmic formulation designed to deliver active pharmaceutical ingredients to the ocular surface.
TP-03 Vehicle is a vehicle used in a pilot study comparing the safety and efficacy of two dosing regimens of TP-03 for the treatment of Meibomian Gland Dysfunction. The study, NCT05454956, also investigated the treatment of Blepharitis, Demodex Infestation, Demodex Infestation of Eyelid, and Demodectic Blepharitis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TP-03 Vehicle |
|---|---|
| Sponsor | Tarsus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
TP-03 Vehicle serves as a pharmaceutical delivery system for ocular therapeutics, optimizing bioavailability and residence time on the eye surface. As a vehicle formulation, it enhances penetration and therapeutic efficacy of the active drug component while minimizing systemic absorption and associated side effects.
Approved indications
- Ocular surface disease (specific indication under investigation in Phase 3)
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD (PHASE2)
- Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study (PHASE3)
- Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex (PHASE2)
- Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE2, PHASE3)
- Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-03 Vehicle CI brief — competitive landscape report
- TP-03 Vehicle updates RSS · CI watch RSS
- Tarsus Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about TP-03 Vehicle
What is TP-03 Vehicle?
How does TP-03 Vehicle work?
What is TP-03 Vehicle used for?
Who makes TP-03 Vehicle?
What development phase is TP-03 Vehicle in?
What are the side effects of TP-03 Vehicle?
Related
- Manufacturer: Tarsus Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Ocular surface disease (specific indication under investigation in Phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing